High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.

Aaron D Fox, Lindsey Riback, Andres Perez-Correa, Eric Ohlendorf, Megan Ghiroli, Czarina Navos Behrends, Teresa López-Castro
{"title":"High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.","authors":"Aaron D Fox, Lindsey Riback, Andres Perez-Correa, Eric Ohlendorf, Megan Ghiroli, Czarina Navos Behrends, Teresa López-Castro","doi":"10.1177/29767342231210552","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Injectable opioid agonist treatment with hydromorphone (iOAT-H) is effective for persons who inject drugs (PWID) with opioid use disorder (OUD) but remains unavailable in the United States. Our objective was to determine interest in iOAT-H among syringe services program (SSP) participants.</p><p><strong>Methods: </strong>We recruited PWID with OUD from SSPs in New York City. Interest in iOAT-H was assessed on a 4-point scale. We compared participants who were and were not interested in iOAT-H regarding sociodemographic characteristics and self-reported variables (past 30 days): heroin use, public injection practices, and participation in illegal activity other than drug possession. Participants reported their preferred OUD treatment and reasons for these preferences.</p><p><strong>Results: </strong>Of 108 participants, most were male (69%), Hispanic (68%), and median age was 42 years. The median number of prior OUD treatment episodes was 6 (interquartile range: 2-12). Most (65%) were interested in iOAT-H. Interested participants (vs not interested) reported, over the prior 30 days, greater heroin use days (mean, 26.4 vs 22.3), injecting in public more times (median, 15 vs 6), and a higher percentage having participated in illegal activity (40% vs 16%). Preferences for OUD treatment were: iOAT-H (43%), methadone (39%), and buprenorphine (9%). Participants who preferred iOAT-H to conventional OUD treatments reported preferring injection as a route of administration and that available OUD treatments helped them insufficiently.</p><p><strong>Conclusions: </strong>SSP participants with OUD reported high interest in iOAT-H. Participants had attempted conventional treatments but still used heroin almost daily. We identified PWID at risk for opioid-related harms who potentially could benefit from iOAT-H.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance use & addiction journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/29767342231210552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Injectable opioid agonist treatment with hydromorphone (iOAT-H) is effective for persons who inject drugs (PWID) with opioid use disorder (OUD) but remains unavailable in the United States. Our objective was to determine interest in iOAT-H among syringe services program (SSP) participants.

Methods: We recruited PWID with OUD from SSPs in New York City. Interest in iOAT-H was assessed on a 4-point scale. We compared participants who were and were not interested in iOAT-H regarding sociodemographic characteristics and self-reported variables (past 30 days): heroin use, public injection practices, and participation in illegal activity other than drug possession. Participants reported their preferred OUD treatment and reasons for these preferences.

Results: Of 108 participants, most were male (69%), Hispanic (68%), and median age was 42 years. The median number of prior OUD treatment episodes was 6 (interquartile range: 2-12). Most (65%) were interested in iOAT-H. Interested participants (vs not interested) reported, over the prior 30 days, greater heroin use days (mean, 26.4 vs 22.3), injecting in public more times (median, 15 vs 6), and a higher percentage having participated in illegal activity (40% vs 16%). Preferences for OUD treatment were: iOAT-H (43%), methadone (39%), and buprenorphine (9%). Participants who preferred iOAT-H to conventional OUD treatments reported preferring injection as a route of administration and that available OUD treatments helped them insufficiently.

Conclusions: SSP participants with OUD reported high interest in iOAT-H. Participants had attempted conventional treatments but still used heroin almost daily. We identified PWID at risk for opioid-related harms who potentially could benefit from iOAT-H.

城市注射器服务计划参与者对使用氢吗啡酮进行阿片类激动剂注射治疗的浓厚兴趣。
背景:注射用阿片类激动剂氢吗啡酮治疗(iOAT-H)对患有阿片类药物使用障碍(OUD)的注射吸毒者(PWID)有效,但在美国仍无法获得。我们的目标是确定注射器服务计划(SSP)参与者对 iOAT-H 的兴趣:我们从纽约市的 SSP 招募了患有 OUD 的吸毒者。对 iOAT-H 的兴趣用 4 点量表进行评估。我们比较了对 iOAT-H 感兴趣和不感兴趣的参与者的社会人口学特征和自我报告变量(过去 30 天):海洛因使用、公共注射行为和参与非法活动(持有毒品除外)。参与者报告了他们对 OUD 治疗的偏好以及偏好的原因:108 名参与者中,大多数为男性(69%)和西班牙裔(68%),年龄中位数为 42 岁。之前接受过 OUD 治疗的次数中位数为 6 次(四分位间范围:2-12 次)。大多数参与者(65%)对 iOAT-H 感兴趣。有兴趣的参与者(与没有兴趣的相比)称,在过去的 30 天里,他们吸食海洛因的天数更多(平均为 26.4 天对 22.3 天),在公共场合注射的次数更多(中位数为 15 次对 6 次),参与非法活动的比例更高(40% 对 16%)。对 OUD 治疗的偏好是:iOAT-H(43%)、美沙酮(39%)和丁丙诺啡(9%)。与传统的 OUD 治疗方法相比,偏好 iOAT-H 的参与者表示更喜欢注射作为给药途径,并认为现有的 OUD 治疗方法对他们的帮助不足:结论:患有 OUD 的 SSP 参与者对 iOAT-H 很感兴趣。参与者尝试过传统治疗方法,但仍几乎每天使用海洛因。我们发现了有可能受到阿片类药物相关伤害的吸毒者,他们有可能从 iOAT-H 中受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信